TY - JOUR
T1 - Validity and responsiveness of a brief, asthma-specific quality-of-life instrument in children with acute asthma
AU - Gorelick, Marc H.
AU - Brousseau, David C.
AU - Stevens, Molly W.
PY - 2004/1
Y1 - 2004/1
N2 - Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79%). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95% confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95% CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.
AB - Objective: To test the validity and short-term responsiveness to change of a pediatric, asthma-specific, health-related quality-of-life (HRQL) instrument. Methods: Children 2 years and older treated in the emergency department (ED) for acute asthma were eligible for this prospective cohort study. A 10-item instrument, the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF), was administered at the time of the ED visit and again 14 days later (via telephone). At the follow-up call, parents were also asked about the child's current overall asthma status, missed school or limited activities, and persistence of asthma symptoms. Results: A total of 121 children were enrolled (mean age, 7.9 years), and follow-up was complete for 96 (79%). Mean ± SD ITG-CASF scores at follow-up were significantly higher among children reported to have improved overall (61.8 ± 19.6) than those not improved (41.9 ± 21.2), and there was a significant correlation between ITG-CASF score at follow-up and the number of days of school missed or limited activities (r = -0.45; 95% confidence interval [CI], -0.24 to -0.66). There was also a significant difference in improvement in ITG-CASF score from ED visit to follow-up among those improved (13.7-point improvement) compared with those not improved (3.3-point improvement; difference = 10.4; 95% CI, 1.2 to 19.5). The effect size was 0.68, indicating a large responsiveness to change. Conclusions: The ITG-CASF is a valid and responsive measure of HRQL in children with acute asthma and may be a useful outcome measure in evaluating ED treatment.
UR - http://www.scopus.com/inward/record.url?scp=1642577218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642577218&partnerID=8YFLogxK
U2 - 10.1016/S1081-1206(10)61709-7
DO - 10.1016/S1081-1206(10)61709-7
M3 - Article
C2 - 14756464
AN - SCOPUS:1642577218
SN - 1081-1206
VL - 92
SP - 47
EP - 51
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 1
ER -